Diurnal Group PLC Director Dealings (1772D)

TIDMDNL

RNS Number : 1772D

Diurnal Group PLC

24 June 2019

24 June 2019

Diurnal Group plc

("Diurnal" or the "Company")

Director Dealings

Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces the following Directors' share purchase on 24 June 2019:

Richard Bungay, Chief Financial Officer, purchased 8,000 Ordinary Shares at a price of 29.75 pence per Ordinary Share. Following the transaction, the total beneficial interest of Richard Bungay is 29,452 Ordinary Shares, representing 0.03% of the total voting rights.

Details of the full notifications received by the Company are set out below:

 
 1     Details of the person discharging managerial responsibilities 
        / person closely associated 
 a)    Name                                    Richard Bungay 
      -------------------------------------  ---------------------------------------- 
 2     Reason for the notification 
      ------------------------------------------------------------------------------- 
 a)    Position/status                        Chief Financial Officer 
      -------------------------------------  ---------------------------------------- 
 b)    Initial notification                   Initial notification 
        /Amendment 
      -------------------------------------  ---------------------------------------- 
 3     Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
      ------------------------------------------------------------------------------- 
 a)    Name                                   Diurnal Group plc 
      -------------------------------------  ---------------------------------------- 
 b)    LEI                                    213800I2HNUNZN1LDH29 
      -------------------------------------  ---------------------------------------- 
 4     Details of the transaction(s): section to be repeated for 
        (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions 
        have been conducted 
      ------------------------------------------------------------------------------- 
 a)    Description of the                     Ordinary shares of 5 pence each in 
        financial instrument,                  Diurnal Group plc 
        type of instrument 
 
       Identification code                    GB00BDB6Q760 
 
 b)    Nature of the transaction              Purchase of ordinary shares 
      -------------------------------------  ---------------------------------------- 
 c)    Price(s) and volume(s) 
                                              ------------------  ----------------- 
                                               Price(s)            Volume(s) 
                                              ------------------  ----------------- 
                                               29.75p              8,000 
                                              ------------------  ----------------- 
 
 d)    Aggregated information 
 
  - Aggregated volume                    As above 
 
  - Price 
 
 e)    Date of the transaction                24 June 2019 
      -------------------------------------  ---------------------------------------- 
 f)    Place of the transaction               XLON 
      -------------------------------------  ---------------------------------------- 
 
 
 For further information, please visit www.diurnal.co.uk or contact: 
 
                                                       [phone] 
 Diurnal Group plc                                      1000 
 Martin Whitaker, Chief Executive Officer 
 Richard Bungay, Chief Financial Officer 
 
 Panmure Gordon (UK) Limited (Nominated Adviser        [phone] 
  and Joint Broker)                                     2500 
 Corporate Finance: Freddy Crossley, Emma Earl 
 Corporate Broking: James Stearns 
 
                                                       [phone] 
 Cantor Fitzgerald Europe (Joint Broker)                7000 
 Corporate Finance: Phil Davies, Will Goode, 
  Michael Boot 
 Healthcare Equity Sales: Andrew Keith 
 
                                                       [phone] 
 FTI Consulting (Media and Investor Relations)          1000 
 Simon Conway 
 Victoria Foster Mitchell 
 

Notes to Editors

About Diurnal Group plc

Founded in 2004, Diurnal is a UK-based specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.

For further information about Diurnal, please visit www.diurnal.co.uk

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHLIFVTRDISFIA

(END) Dow Jones Newswires

June 24, 2019 04:39 ET (08:39 GMT)